Overview of the drug development for hemochromatosis
It has been observed that Hemochromatosis is a disorder in which the body simply loads too much iron from the diet. It occurs either by mutations in the gene or by other medical conditions such as anemia, chronic liver disease, and kidney dialysis. Mostly, the disease occurs due to the mutations in the C282Y and TMPRSS6 genes in the body. There are different types of hemochromatosis including hereditary hemochromatosis, juvenile hemochromatosis, neonatal hemochromatosis, and secondary hemochromatosis. Various symptoms of the disease include abdominal pain, fatigue, joint pain, liver failure, and weakness. Eventually, with the rising incidences of the syndrome, the need for the drug development for hemochromatosis is likely to surge considerably in the forthcoming years.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for hemochromatosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hemochromatosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
Therapeutic assessment of the drug development for hemochromatosis by route of administration
The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development for hemochromatosis by therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug development for hemochromatosis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
What are the drug molecules in the various development stages for Hemochromatosis?
What are the companies that are currently involved in the development of drug molecules for Hemochromatosis?
Insight into discontinued/inactive molecules with appropriate reasoning?
What are the major regulatory authorities approving drugs in various regions?
Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.